Tags

Type your tag names separated by a space and hit enter

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
J Psychopharmacol. 2011 Jan; 25(1):121-30.JP

Abstract

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the present study was to investigate this in patients with generalized social anxiety disorder (SAD) using functional neuroimaging. Regional cerebral blood flow (rCBF) at rest was measured twice using (99m)Tc-ECD SPECT in 10 treatment-naïve patients with SAD. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping. Relative to placebo, CBD was associated with significantly decreased subjective anxiety (p < 0.001), reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus (p < 0.001, uncorrected), and increased ECD uptake in the right posterior cingulate gyrus (p < 0.001, uncorrected). These results suggest that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas.

Authors+Show Affiliations

Department of Neurosciences and Behavior, Division of Psychiatry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. jcrippa@fmrp.usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20829306

Citation

Crippa, José Alexandre S., et al. "Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: a Preliminary Report." Journal of Psychopharmacology (Oxford, England), vol. 25, no. 1, 2011, pp. 121-30.
Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-30.
Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., Santos Filho, A., Freitas-Ferrari, M. C., McGuire, P. K., Zuardi, A. W., Busatto, G. F., & Hallak, J. E. (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology (Oxford, England), 25(1), 121-30. https://doi.org/10.1177/0269881110379283
Crippa JA, et al. Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: a Preliminary Report. J Psychopharmacol. 2011;25(1):121-30. PubMed PMID: 20829306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. AU - Crippa,José Alexandre S, AU - Derenusson,Guilherme Nogueira, AU - Ferrari,Thiago Borduqui, AU - Wichert-Ana,Lauro, AU - Duran,Fábio L S, AU - Martin-Santos,Rocio, AU - Simões,Marcus Vinícius, AU - Bhattacharyya,Sagnik, AU - Fusar-Poli,Paolo, AU - Atakan,Zerrin, AU - Santos Filho,Alaor, AU - Freitas-Ferrari,Maria Cecília, AU - McGuire,Philip K, AU - Zuardi,Antonio Waldo, AU - Busatto,Geraldo F, AU - Hallak,Jaime Eduardo Cecílio, Y1 - 2010/09/09/ PY - 2010/9/11/entrez PY - 2010/9/11/pubmed PY - 2011/7/19/medline SP - 121 EP - 30 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 25 IS - 1 N2 - Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the present study was to investigate this in patients with generalized social anxiety disorder (SAD) using functional neuroimaging. Regional cerebral blood flow (rCBF) at rest was measured twice using (99m)Tc-ECD SPECT in 10 treatment-naïve patients with SAD. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping. Relative to placebo, CBD was associated with significantly decreased subjective anxiety (p < 0.001), reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus (p < 0.001, uncorrected), and increased ECD uptake in the right posterior cingulate gyrus (p < 0.001, uncorrected). These results suggest that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/20829306/Neural_basis_of_anxiolytic_effects_of_cannabidiol__CBD__in_generalized_social_anxiety_disorder:_a_preliminary_report_ L2 - https://journals.sagepub.com/doi/10.1177/0269881110379283?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -